Welcome to our dedicated page for Scholar Rock Holding Corporation news (Ticker: SRRK), a resource for investors and traders seeking the latest updates and insights on Scholar Rock Holding Corporation stock.
Scholar Rock Holding Corporation (SRRK) is a biotechnology company dedicated to pioneering a novel class of biologic therapies known as 'niche modulators'. These therapies selectively target the activation of growth factors within the disease microenvironment, offering a groundbreaking approach to treating serious medical conditions. Scholar Rock's initial proprietary and partnered drug discovery programs focus on specific growth factors, particularly members of the TGF-beta superfamily, which are critical in regulating cell growth and differentiation. These growth factors are notably present in the microenvironments of significant diseases like fibrosis, musculoskeletal disorders, and autoimmune diseases.
The company’s innovative therapeutic strategy stems from the foundational scientific discoveries of its founders, Professors Timothy Springer, PhD, and Leonard Zon, MD, from Children's Hospital Boston and Harvard Medical School. These discoveries illuminate the molecular mechanisms of growth factor activation, empowering Scholar Rock to advance its ground-breaking treatments.
Scholar Rock is backed by a consortium of top-tier life sciences investors, including Polaris Partners and Arch Venture Partners. Its flagship product candidate, Apitegroma, is a selective, fully human, monoclonal antibody that inhibits the activation of the growth factor myostatin in skeletal muscle. This innovative mechanism holds promise for treating neuromuscular disorders. Another key product in the company's pipeline is SRK-181, which targets the activation of latent transforming growth factor beta-1 (TGFβ1) and is being developed to treat cancers that are resistant to existing anti-PD-(L)1 antibody therapies.
With its operations based in the United States, Scholar Rock continues to make significant strides in the biopharmaceutical industry, pushing the envelope of medical science and offering hope for effective treatments against some of the most challenging diseases.
Scholar Rock (NASDAQ: SRRK) has granted inducement equity awards to three new employees, comprising stock options for 27,429 shares and restricted stock units for 20,571 shares, totaling 48,000 shares of common stock. The awards are part of the company's 2022 Inducement Equity Plan, specifically designed for new hires.
The inducement stock options were priced at $42.60, matching the closing price on January 13, 2025. The vesting schedule includes 25% of shares vesting on the first employment anniversary, with the remaining 75% vesting in 12 quarterly installments. The restricted stock units will vest in four equal annual installments, contingent on continued employment.
Scholar Rock (SRRK) outlined its 2025 strategic priorities, focusing on three key areas: commercializing apitegromab in SMA, expanding its benefits, and advancing their anti-myostatin program in cardiometabolic disorders. The company plans to submit BLA and MAA applications for apitegromab in Q1 2025, with U.S. launch expected in Q4 2025.
Key upcoming milestones include initiating the Phase 2 OPAL trial in SMA patients under two years old in mid-2025, expecting data from Phase 2 EMBRAZE obesity trial in Q2 2025, and filing an IND application for SRK-439 in Q3 2025. The company reported positive topline data from the SAPPHIRE trial in October 2024, showing significant improvement in motor function for SMA patients.
Scholar Rock's financial position remains strong, with funding expected to last into Q4 2026, supported by a successful $345 million public offering completed in October.
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company specializing in treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and diseases involving protein growth factors, has announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference.
The presentation is scheduled for Tuesday, January 14, 2025, at 9:45 a.m. PT (12:45 p.m. ET). Interested parties can access a live webcast through the Investors & Media section of Scholar Rock's website. The presentation recording will remain available on the company's website for approximately 90 days following the event.
Scholar Rock (NASDAQ: SRRK) has granted inducement equity awards to twelve new employees, totaling 208,800 shares of common stock. The awards consist of 119,312 shares as stock options with an exercise price of $45.48 and 89,488 shares as restricted stock units. The stock options will vest 25% after one year, with the remaining 75% vesting in 12 quarterly installments. The restricted stock units will vest in four equal annual installments. These grants were made under the Company's 2022 Inducement Equity Plan, specifically designed for new hires as per Nasdaq Listing Rule 5635(c)(4).
Scholar Rock (NASDAQ: SRRK) has granted inducement equity awards to four new employees, including stock options for 57,429 shares and restricted stock units for 43,071 shares. The stock options, priced at $28.15 per share, will vest 25% after one year and the remaining 75% in quarterly installments. The restricted stock units will vest in four equal annual installments. These grants, made under the company's 2022 Inducement Equity Plan, are designed to attract new talent to the late-stage biopharmaceutical company, which focuses on treatments for spinal muscular atrophy and cardiometabolic disorders.
Scholar Rock (SRRK) reported positive Phase 3 SAPPHIRE trial results for apitegromab in Spinal Muscular Atrophy (SMA), achieving its primary endpoint with statistically significant motor function improvement. The company plans to submit BLA and MAA applications in Q1 2025. The Phase 2 EMBRAZE obesity trial enrollment is complete with data expected in Q2 2025. Financial highlights include completion of a $345M public offering and Q3 2024 net loss of $64.5M ($0.66/share). Cash position stands at $139.1M, with pro forma balance of $463.5M including October offering, extending runway into Q4 2026.
Scholar Rock (NASDAQ: SRRK) announced new preclinical data for SRK-439, showing significant lean mass increase and enhanced fat mass loss when combined with metformin. In young mice, the combination treatment demonstrated a 31.6% increase in lean mass compared to 15.1% in controls, while older mice showed a 10.2% increase versus 0.2% in controls. The study also revealed lower fat mass gain in young mice receiving the combination treatment (68.2% increase) compared to metformin alone (114% increase). These results support the potential of selective myostatin inhibition in improving body composition for obesity treatment. The company's Phase 2 EMBRAZE trial is on track for readout in Q2 2025.
Scholar Rock (NASDAQ: SRRK) announced it will host a conference call to discuss third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024, at 8:15am ET. The company, which focuses on developing treatments for spinal muscular atrophy, cardiometabolic disorders, and other diseases involving protein growth factors, will make the audio webcast available on their investor relations website. Participants can register online to join via telephone or web.
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focusing on treatments for spinal muscular atrophy, cardiometabolic disorders, and diseases involving protein growth factors, has announced its participation in three upcoming investor conferences. The company will present at the Truist Securities BioPharma Symposium on November 7, the Jefferies London Healthcare Conference on November 20, and the Piper Sandler Healthcare Conference on December 4. Live webcasts will be available on Scholar Rock's website, with replays accessible for approximately 90 days.
Scholar Rock (NASDAQ: SRRK) announced it will present new data from the Phase 1 DRAGON trial of SRK-181, an investigational selective inhibitor of latent TGFβ1 activation, at the SITC 39th Annual Meeting. The presentation will include updated safety, efficacy, and biomarker results for SRK-181 in anti-PD-1 resistant patients with advanced solid tumors from the expansion phase (Part B) of the trial. The company reports observing durable responses in heavily pretreated patients, with some patients remaining on therapy after the trial completed enrollment last year.
FAQ
What is the current stock price of Scholar Rock Holding Corporation (SRRK)?
What is the market cap of Scholar Rock Holding Corporation (SRRK)?
What is Scholar Rock Holding Corporation's main focus?
What are niche modulators?
Who founded Scholar Rock?
What is Apitegroma?
What diseases does Scholar Rock target?
What is SRK-181?
Who are some of Scholar Rock's investors?
Where is Scholar Rock based?
What is the therapeutic approach of Scholar Rock?
What recent achievements has Scholar Rock made?
